Enhancing the Safety of Warfarin in Nursing Homes
NCT00682773 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26
Last updated 2011-08-04
Summary
Oral anticoagulant therapy with warfarin is essential for the prevention of strokes and other thromboembolic events related to various medical conditions; however, use of this therapy can be associated with an increased risk of serious bleeding. In a previous AHRQ-funded study, we have demonstrated that the prevalence of conditions for which warfarin is indicated is high among frail elderly nursing homes residents, use of warfarin in this setting is very common, and the quality and safety with which warfarin is used is far from optimal. The research described in this application resonates with AHRQ's stated priorities for FY2006. The premise underlying the proposed intervention study is that errors in prescribing and monitoring warfarin for nursing home residents are related more to problems in the system of care, than to deficits in the knowledge base of health care providers. We propose a low technology intervention for improving the quality and safety of anticoagulant therapy with warfarin in the nursing home setting. The intervention focuses on maximizing the effectiveness of communication between the nursing staff and physicians of nursing home residents on warfarin. The intervention will build on an established approach for situation briefing drawn from the U.S. armed forces: SBAR - Situation, Background, Assessment, Recommendation. We will test the effectiveness of this approach through a matched, cluster-randomized trial, with randomization at the level of the nursing home. Our study has the following specific aims: (1) to determine whether a nursing home warfarin management protocol emphasizing facilitated communication to physicians will improve the quality of anticoagulation management, which will be assessed using widely accepted quality measures; (2) to determine whether the intervention will lower the rates of adverse events (bleeds and thromboembolic events) among warfarin-treated residents of intervention group nursing homes compared to control nursing homes; and (3) to produce a toolkit for use by nursing homes that will allow dissemination of this approach to enhancing the quality and safety of warfarin for the frail elderly. If successful, this approach may serve as a model for improving the safety of other medication categories associated with high rates of preventable adverse drug events, and for protecting nursing home residents, and frail elderly cared for in other settings, who are at special risk for medication-related problems.
Conditions
- Adverse Drug Events (ADEs)
Interventions
- OTHER
-
SBAR
Educational intervention for nursing staff on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
Sponsors & Collaborators
-
Agency for Healthcare Research and Quality (AHRQ)
collaborator FED -
Qualidigm
collaborator INDUSTRY -
University of Massachusetts, Worcester
lead OTHER
Principal Investigators
-
Jerry H Gurwitz, MD · Meyers Primary Care Institute/University of Massachusetts Medical School
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2006-09-30
- Primary Completion
- 2008-12-31
- Completion
- 2009-09-30
Countries
- United States
Study Locations
More Related Trials
-
Warfarin - How Good Are we at Maintaining Target Range ?
NCT01081327 ·Status: COMPLETED
-
Pharmacogenetic Dosing of Warfarin
NCT02065388 ·Status: COMPLETED ·Phase: PHASE3
-
Safer Warfarin Treatment
NCT01042067 ·Status: SUSPENDED
-
Association Between Genetic Variant Scores and Warfarin Effect
NCT03894878 ·Status: COMPLETED
-
Direct Oral Anticoagulants and Venous Thromboembolism
NCT02833987 ·Status: COMPLETED
-
Factors Associated to the Instability of the INR (International Normalized Ratio ) in the Prevention of Thromboembolism AVK (Anti Vitamin K) in Atrial Fibrillation in the Elderly: Instead of Comorbidities
NCT02841475 ·Status: COMPLETED
-
Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over
NCT02286414 ·Status: COMPLETED
-
Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
NCT00005684 ·Status: COMPLETED
-
Following Patients on Warfarin Therapy to See if Differences in Hemorrhagic Complications Exist
NCT00075985 ·Status: COMPLETED
-
Protocol for Improvement of Therapy With Warfarin
NCT06789588 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Pharmacogenetics of Acenocoumarol
NCT01492777 ·Status: COMPLETED
-
Comparative Effectiveness and Safety Between Warfarin and Dabigatran
NCT03254134 ·Status: COMPLETED
-
Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid
NCT00603317 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacogenetic Study of Warfarin Dose-Response: a Prospective Trial
NCT00654823 ·Status: UNKNOWN
-
Warfarin Patient Self-management Implementation in the US Healthcare System
NCT04766216 ·Status: RECRUITING ·Phase: NA
-
Prospective Evaluation of Bleeding Risk of Anticoagulant and Anti-platelet Therapy
NCT00625248 ·Status: COMPLETED
-
Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters
NCT00024297 ·Status: COMPLETED ·Phase: NA
-
A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants
NCT04394234 ·Status: COMPLETED
-
Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty
NCT04878497 ·Status: UNKNOWN
-
Daily Vitamin K in Patients on Warfarin With Unstable INRs
NCT00287313 ·Status: COMPLETED ·Phase: NA
-
Edoxaban and Frailty in Senior Individuals
NCT03524924 ·Status: COMPLETED
-
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
NCT01305148 ·Status: SUSPENDED ·Phase: NA
-
Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm
NCT00511173 ·Status: COMPLETED ·Phase: PHASE4
-
Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin
NCT00927862 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR
NCT00247702 ·Status: UNKNOWN ·Phase: NA